Skip to Content

Workers’ Compensation Board

Search menu

Save the Date – COVID-19 and Workers’ Compensation Webinar

Subject Number 046-1367 Temporary Suspension of Dr. Howard Adelglass

Subject Numbers Regarding Health Provider Authorizations

Authorization No. 148023-5W

February 3, 2021

Pursuant to Workers’ Compensation Law Section 13-d(4), the Chair of the New York State Workers’ Compensation Board has exercised her authority to temporarily suspend Dr. Howard Adelglass’ authorization to treat injured workers within the New York State workers’ compensation system effective January 26, 2021. Dr. Adelglass’ last known business addresses are:

200 Central Park South, Suite 212
New York, New York 10019


1221 Jerome Avenue
Bronx, New York 10452

The Chair’s designee’s investigation has revealed that the New York State Department of Health, State Board for Professional Medical Conduct (BPMC) has issued Commissioner’s Order of Summary Action # 20-318, prohibiting Dr. Adelglass from practicing medicine in the State of New York or in any setting under the authority of his New York license, pending the final conclusion of a hearing regarding allegations brought in the United States District Court, Southern District of New York, including that he conspired to unlawfully distribute more than one million pills of the Schedule II controlled substance oxycodone to individuals he knew had no medical need for them, in violation of Title 21 United States Code, Sections 841(a)(1), and 841(b)(1)(c).

Therefore, the Chair believes that Dr. Adelglass may be guilty of misconduct, and that such misconduct would detrimentally affect the quality of care provided to injured workers.

Dr. Adelglass is prohibited from rendering treatment and care to injured workers, or to conduct reviews of records regarding variance requests pursuant to 12 NYCRR § 324.3(b)(2)(ii)(a), while his authorization is temporarily suspended. Reports submitted by Dr. Adelglass for services rendered prior to January 26, 2021, are valid but are invalid for any services rendered on or after that date. Requests to cross-examine Dr. Adelglass for services rendered prior to January 26, 2021, should not be denied due to the suspension of his authorization.

This suspension remains in effect until further notice. Any questions regarding the authorized lists should be referred to the Medical Director’s Office at 1 (800) 781-2362.

Clarissa M. Rodriguez